Achieve Life Sciences (NASDAQ:ACHV) and Century Therapeutics (NASDAQ:IPSC) Head to Head Analysis

Century Therapeutics (NASDAQ:IPSC) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Risk & Volatility

Century Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares Century Therapeutics and Achieve Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	-19.10%	-11.53%	-6.94%
Achieve Life Sciences	N/A	-193.49%	-116.68%

Insider and Institutional Ownership

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 5.0% of Century Therapeutics shares are held by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Century Therapeutics and Achieve Life Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$6.59 million	7.76	-$126.57 million	($0.29)	-2.04
Achieve Life Sciences	N/A	N/A	-$39.83 million	($1.46)	-3.59

Achieve Life Sciences has lower revenue, but higher earnings than Century Therapeutics. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Century Therapeutics and Achieve Life Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1	0	4	0	2.60
Achieve Life Sciences	1	0	2	1	2.75

Century Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 533.45%. Achieve Life Sciences has a consensus price target of $12.00, indicating a potential upside of 129.01%. Given Century Therapeutics’ higher possible upside, equities research analysts plainly believe Century Therapeutics is more favorable than Achieve Life Sciences.

Summary

Century Therapeutics beats Achieve Life Sciences on 10 of the 14 factors compared between the two stocks.

About Century Therapeutics

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

About Achieve Life Sciences

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.